Register entry
- Registered sites
- 0
- Active NDC listings
- 11
- Live patents
- 21
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
1111 active NDC listings: 9 human prescription drug, 2 drug for further processing. By marketing category: NDA 9, DRUG FOR FURTHER PROCESSING 2.
| Dosage form | NDCs |
|---|---|
| cream | 3 |
| gel | 3 |
| tablet, coated | 3 |
| ointment | 1 |
| tape | 1 |
| Route | NDCs |
|---|---|
| cutaneous | 5 |
| topical | 3 |
| oral | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| almirall, llc | 11 |
Exclusivity
Patents and exclusivities
21| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7875630 | ALTABAXretapamulin | substance | Feb 2027 |
| 10323001 | KLISYRItirbanibulin | product | Dec 2027 |
| 9481639 | SEYSARAsarecycline hydrochloride | use | Aug 2028 |
| 7851470 | KLISYRItirbanibulin | substance, product | Feb 2029 |
| 8513223 | SEYSARAsarecycline hydrochloride | use | Dec 2029 |
| 7300931 | KLISYRItirbanibulin | substance, product | Dec 2030 |
| 8318706 | SEYSARAsarecycline hydrochloride | substance, product | Jan 2032 |
| 9255068 | SEYSARAsarecycline hydrochloride | substance, product | Feb 2033 |
| 11273132 | ACZONEdapsone | product | Nov 2033 |
| 10617693 | KLISYRItirbanibulin | use | Mar 2038 |
| 11497750 | KLISYRItirbanibulin | use | Mar 2038 |
| 12667576 | KLISYRItirbanibulin | use | Mar 2038 |
| 10669236 | KLISYRItirbanibulin | substance, product | Sept 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| KLISYRITIRBANIBULIN | D-192 New dosing schedule | Jun 2027 |
Catalogue
Marketed products
11| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| AZELEX | azelaic acid | cream, cutaneous | 16110-869NDA |
| Aczone | dapsone | gel, topical | 16110-526NDA |
| CORDRAN | flurandrenolide | tape, topical | 16110-587NDA |
| Klisyri | tirbanibulin | ointment, topical | 16110-391NDA |
| Seysara | sarecycline hydrochloride | tablet, coated, oral | 16110-246NDA |
| TAZORAC | tazarotene | cream, cutaneous | 16110-915NDA |
| TAZORAC | tazarotene | cream, cutaneous | 16110-916NDA |
| Tazorac | tazarotene | gel, cutaneous | 16110-042NDA |
| Tazorac | tazarotene | gel, cutaneous | 16110-833NDA |
| - | sarecycline hydrochloride | tablet, coated | 16110-245DRUG FOR FURTHER PROCESSING |
| - | sarecycline hydrochloride | tablet, coated | 16110-247DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing tazarotene
- Padagis Israel Pharmaceuticals Ltd2 sites · 236 NDC
- Bryant Ranch Prepack1 site · 4,357 NDC
- Bausch Health US, LLC1 site · 93 NDC
- Mayne Pharma International Pty Ltd.1 site · 64 NDC
- Cosette Pharmaceuticals, Inc.0 sites · 95 NDC
Enquiry
Common questions
- Is Almirall, LLC FDA approved?
- Almirall, LLC holds no registered establishment of its own; 11 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Almirall, LLC make?
- 11 products are listed under Almirall, LLC in the openFDA NDC Directory, most often as cream; gel; tablet, coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.